Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRT3789 · 1 trial · 4 indications
Dose limiting toxicities will be evaluated over the 21-day observation period
Safety and tolerability will be evaluated by incidence of DLTs, laboratory measurements, dose interruption, modification, and discontinuation due to adverse events (AEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
The MTD/RP2D will be established for further investigation in participants with advanced solid tumors
| Arm | Type | Description |
|---|---|---|
| PRT3789 Monotherapy | EXPERIMENTAL | PRT3789 will be administered by intravenous infusion |
| PRT3789/Docetaxel Combination | EXPERIMENTAL | PRT3789 and Docetaxel will be administered by intravenous infusions |
| Name | Type | Description |
|---|---|---|
| PRT3789 | DRUG | PRT3789 will be administered by intravenous infusion |
| Docetaxel | DRUG | Docetaxel will be administered by intravenous infusion |
Inclusion Criteria: * Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations (including contraception requirements), and other study procedures * Histologically confirmed advanced, recurrent, or metastatic solid tumor malignancy with any mut...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
PRT3789 is an investigational small molecule being developed for the treatment of advanced solid tumors, including metastatic solid tumors and non-small cell lung cancers. It is specifically being studied in patients whose tumors carry a SMARCA4 gene mutation. The drug is currently in Phase 1 clinical development.
PRT3789 is being studied in patients with SMARCA4 gene mutations. The drug is designed to target tumors that harbor this specific genetic alteration, which is a key focus of its clinical development program in advanced solid tumors.
PRT3789 is being developed by Prelude Therapeutics Incorporated, a biopharmaceutical company listed on the stock exchange under the ticker symbol PRLD. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with advanced solid tumors.
PRT3789 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing clinical program is evaluating the drug as a monotherapy and in combination with docetaxel for advanced solid tumors.
PRT3789 is being studied in clinical trial NCT05639751, titled 'PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation.' This Phase 1 trial has enrolled 135 participants and has been completed. The study was conducted in the United States, France, Netherlands, Singapore, and Spain.
Yes, PRT3789 is being evaluated both as a monotherapy and in combination with docetaxel. The clinical trial NCT05639751 is investigating these treatment approaches in patients with advanced or metastatic solid tumors that have a SMARCA4 gene mutation.